Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2024-09-24 00:00:00 ET · period of report 2024-09-20 · accession 0002001011-24-000087 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-09-24 | 2024-09-20+ | LGND | Korenberg Matthew E | Pres, COO | M - OptEx | $51.80 | +14.8K | 57.1K | +35% | +$764.3K |
| DM | 2024-09-24 | 2024-09-20+ | LGND | Korenberg Matthew E | Pres, COO | S - Sale+OE | $102.35 | -16.0K | 50.8K | -24% | -$1.64M |
| DM | 2024-09-24 | 2024-09-20+ | LGND | Korenberg Matthew E | Pres, COO | M - OptEx | $0.00 | -14.8K | 42.4K | -26% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-23 | M | A | 395 | $49.99 | 51,172 | D | — | — | |
| 2 | Common | Common Stock | 2024-09-23 | M | A | 9,377 | $52.84 | 60,549 | D | — | — | |
| 3 | Common | Common Stock | 2024-09-23 | S | D | 201 | $102.05 | 50,777 | D | — | — | (F4) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $102.0450 to $102.0950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2024-09-20 | M | A | 4,982 | $49.99 | 57,052 | D | — | — | |
| 5 | Common | Common Stock | 2024-09-23 | S | D | 2,481 | $100.05 | 58,068 | D | — | — | (F2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $100.0000 to $100.2750. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 6 | Common | Common Stock | 2024-09-23 | S | D | 7,090 | $101.61 | 50,978 | D | — | — | (F3) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $101.0450 to $102.0400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 7 | Common | Common Stock | 2024-09-20 | S | D | 6,275 | $104.10 | 50,777 | D | — | — | (F1) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $104.0000 to $104.4300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 8 | Derivative | Employee Stock Option (right to buy) | 2024-09-20 | M | D | 4,982 | $0.00 | 395 | D | $49.99 · — to 2026-02-11 | 4,982 Common Stock | (F5) This Option was previously reported as a Grant of 18,464 shares on February 11, 2016, which vested in full on February 11, 2020, at an exercise price of $85.79 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |
| 9 | Derivative | Employee Stock Option (right to buy) | 2024-09-23 | M | D | 395 | $0.00 | 0 | D | $49.99 · — to 2026-02-11 | 395 Common Stock | (F5) This Option was previously reported as a Grant of 18,464 shares on February 11, 2016, which vested in full on February 11, 2020, at an exercise price of $85.79 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |
| 10 | Derivative | Employee Stock Option (right to buy) | 2024-09-23 | M | D | 9,377 | $0.00 | 42,436 | D | $52.84 · — to 2032-05-05 | 9,377 Common Stock | (F6) This Option was previously reported as a Grant of 30,189 shares on May 5, 2022, at an exercise price of $90.68 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer and shall be fully vested on February 5, 2026. |